A preliminary study suggests that the combination of enfortumab vedotin and pembrolizumab may be a promising option for treating urothelial cancer.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Home News Thomas Flaig, MD, on Novel Combination Therapy for Advanced Urothelial Cancer back to News
minute read
A preliminary study suggests that the combination of enfortumab vedotin and pembrolizumab may be a promising option for treating urothelial cancer.
Topics: Press Coverage
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.